- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12,537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced May 22, 2026, 3:51 AM EDT